Enhertu, Datroway and other antibody-drug conjugates developed by Daiichi Sankyo have made the company a leader in a ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics License Application (BLA) seeking accelerated approval in the U.S. for ...

MSD (known as Merck & Co in the US and Canada ... which accounted for $1.5 billion of that upfront fee. Daiichi Sankyo's head of global R&D, Ken Takeshita, said that EGFR-mutated NSCLC is known ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Daiichi Sankyo has signed a deal worth up to $300 ... Financial terms of the Sandoz agreement were not disclosed, but MSD (known as Merck & Co in the US and Canada) paid $20 million upfront ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

Daiichi pull US application for 'guided missile' therapy for lung cancer Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Researchers at ASCO provided a look at DB-1310 and iza-bren in genomically altered NSCLC, amid an overall survival miss for ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...